Fatty Liver Treatment Market Size, Share Analysis, Global Report 2024-2033

The fatty liver treatment market size has grown strongly in recent years. It will grow from $22.17 billion in 2023 to $23.58 billion in 2024 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to obesity epidemic, sedentary lifestyles, unhealthy diets, limited treatment options, awareness campaigns.

The fatty liver treatment market size is expected to see strong growth in the next few years. It will grow to $30.11 billion in 2028 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to increased disease prevalence, rising healthcare expenditure, growing diabetes and metabolic syndrome, innovation in therapeutics. Major trends in the forecast period include precision medicine approaches, lifestyle modification programs, targeted therapies for nash, non-invasive monitoring tools, technological advancements.

Market Overview -
Fatty liver disease is a condition in which fat builds up in the liver, causing various symptoms and complications. Fatty liver treatment refers to the multiple strategies, interventions, and actions to address and manage fatty liver disease.

Download Free Sample of Report -

https://www.thebusinessresearchcompany.com/sample.aspx?id=12581&type=smp

The Increase In Alcohol Consumption
The increase in alcohol consumption is expected to propel the growth of the fatty liver treatment market going forward. Alcohol consumption refers to consuming beverages containing alcohol, a psychoactive substance with depressant effects on the central nervous system. Alcohol consumption can worsen fatty liver disease and lead to more severe liver conditions, including alcoholic fatty liver disease (AFLD) and alcoholic hepatitis. For instance, in December 2022, according to a report published by Kirin Holdings Company Limited, a Japan-based beverages company, about 185.60 million kiloliters of beer were consumed worldwide in 2021, a rise of 4.0% from 2020. Therefore, the increase in alcohol consumption is driving the growth of the fatty liver treatment market.

Competitive Landscape -
Major companies operating in the fatty liver treatment market report are Pfizer Inc., Johnson & Johnson Services Inc., Hoffmann La Roche Ltd., AstraZeneca plc, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., The Bristol-Myers Squibb Company, GlaxoSmithkline plc, Mitsubishi Chemical Holdings, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Novo Nordisk A/S, Eisai Co. Ltd., Zydus Lifesciences Limited, Glenmark Pharmaceuticals Limited, GW Pharmaceuticals Limited, Retrophin Inc., Alnylam Pharmaceuticals Inc., Intercept Pharmaceuticals Inc., AbbKine Scientific Co. Ltd., Daewoong Co. Ltd., Madrigal Pharmaceuticals Inc., Orchid Chemicals & Pharmaceuticals Limited, Genfit, NGM Biopharmaceuticals Inc., Cardax Inc., Conatus Pharmaceuticals Inc., Limerick Biopharma Inc.

Pioneering Product Innovations To Transform The Market Landscape
Product innovation is a key trend gaining popularity in the fatty liver treatment market. Major companies operating in fatty liver treatment are developing innovative products to strengthen their position in the market. For instance, in March 2023, Akero Therapeutics, a US-based biotechnology company, reported positive Phase II reports of efruxifermin, indicated for the treatment of non-invasively diagnosed nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). It is a differentiated Fc-FGF21 fusion protein that mimics the biological activity of fibroblast growth factor 21 (FGF21), which regulates multiple metabolic pathways and cellular processes.

Browse Full Report @

https://www.thebusinessresearchcompany.com/report/fatty-liver-treatment-global-market-report

Key Segments -

The fatty liver treatment market covered in this report is segmented -

1) By Treatment Type: Anti-Rejection Drugs Or Immunosuppressants, Chemotherapy Drugs, Targeted Therapy, Vaccines, Anti-Viral Drugs
2) By Disease Type: Hepatitis, Liver Cancer, Non-Alcoholic Fatty Liver Disease, Other Diseases
3) By End User: Hospitals, Ambulatory Surgery Centers, Other End Users

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.